|
- Mirvetuximab Soravtansine for Ovarian Cancer - WebMD
Many people with epithelial ovarian cancer (EOC) respond to treatment at first But cancer comes back, or recurs, in up to 80% of those who get better Over time, a common treatment for advanced
- Mirvetuximab Soravtansine-Gynx Approved for Ovarian Cancer
Although people with advanced ovarian cancer can initially be treated successfully with platinum-based chemotherapy drugs, the cancer often comes back Platinum-resistant ovarian cancer has proven difficult to treat, but with the Food and Drug Administration’s recent full approval of mirvetuximab soravtansine-gynx (Elahere), some people in this situation now have a new treatment option
- FDA Approval Summary: Mirvetuximab soravtansine-gynx for FRα-positive . . .
Mirvetuximab soravtansine-gynx is the first ADC approved for the treatment of ovarian cancer as well as the first targeted therapy approved for FRα-positive PROC Patients with PROC have limited treatment options, and there is an urgent need for safe and effective new therapies Mirvetuximab soravtansine-gynx was associated with a confirmed
- Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian . . .
Mirvetuximab soravtansine-gynx (MIRV) is a first-in-class antibody–drug conjugate targeting folate receptor α (FRα), a biomarker that is commonly overexpressed on ovarian carcinomas and
- Mirvetuximab soravtansine: A breakthrough in targeted therapy for . . .
Ovarian cancer, ranked as the second leading cause of gynecologic malignancy-related deaths globally, poses a formidable challenge despite advances in early detection and treatment modalities This paper explores the efficacy and safety of mirvetuximab soravtansine, the first folate receptor alpha (FRα)-targeting antibody-drug conjugate, in
- Considering Elahere For Your Ovarian Cancer? Heres What . . . - SurvivorNet
RELATED: Ovarian Cancer: Overview Platinum-based chemotherapies, such as cisplatin and carboplatin are a cornerstone of ovarian cancer treatment Far too often, however, these cancers can evolve and become resistant to these traditional medications Ovarian cancer is termed resistant when it returns within 6 months of treatment initiation
- ELAHERE® (mirvetuximab soravtansine-gynx) | HCP Website
For patients with FRα +, platinum-resistant ovarian cancer, ELAHERE is the first treatment to show statistically significant improvements vs standard single-agent chemotherapy 1-3 * Median PFS: 5 6 months vs 4 0 months, P0 0001 † Median OS: 16 5 months vs 12 7 months, P=0 0046 ‡ ORR: 42% vs 16%, P0 0001 § View the Data
- First Targeted Therapy for Platinum-Resistant Ovarian Cancer to Improve . . .
This is the first antibody-drug conjugate with proven efficacy in ovarian cancer and the only approved biomarker-driven therapy for platinum-resistant ovarian cancer ” Mirvetuximab soravtansine is an antibody-drug conjugate targeting FR-alpha and conjugated to the highly potenttubulin inhibitor, DM4
|
|
|